Carcinoma, Pancreatic Ductal Clinical Trial
Official title:
Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence
It is hypothesized that circulating tumor cells (CTCs) from pancreatic adenocarcinoma are released into the peritoneal cavity through blood lost during the surgical resection of these tumors resulting in peritoneal recurrence despite appropriate surgical resection. Targeting the mechanisms responsible for CTC adhesion to the peritoneum may result in inhibition of implantation and growth, thus preventing this mode of pancreatic cancer recurrence postoperatively.
Research Plan:
Intraoperative Subjects with Pancreatic Ductal Adenocarcinoma (PDAC) who have been consented
and enrolled into the study will be taken to the operating room (OR) for their previously
planned pancreatectomy procedure. After general anesthesia is induced, using universal
precautions, blood sample (10ml) will be collected into a heparin tube for identification of
circulating tumor cells (CTCs) and serve as one of two controls designed to assess
background CTC counts. Once the participant has undergone surgical exploration as planned
and has been deemed a candidate for resection, normal saline will be used to wash the
abdominal cavity and collected in a suction canister by the attending surgeon. Abdominal
washings are a normal part of the operative procedure, typically performed at the end of the
operation to wash blood out of the abdominal cavity and is performed with variable amounts
depending on the surgeon's discretion. For purposes of a control for the study, this wash
step will be moved to the beginning of the operation. Additional washes/irrigations may be
necessary at the end of the case at the surgeon's discretion. Cells collected in this fluid
will be centrifuged and collected in the lab for determination of the presence of malignant
cells. This will serve as the second of two controls. As the pancreatectomy procedure
proceeds, subject blood will be lost as a normal consequence of the procedure and suctioned
from the operative field into a new container containing heparin chilled on ice to preserve
cell viability. This blood is normally discarded at the end of the case but a portion of the
blood will be collected and utilized for downstream lab experiments to detect CTCs.
Laboratory/Post-Processing Blood collected in the operating room as described above will be
immediately brought to the laboratory and centrifuged to separate out the plasma, buffy
coat, and erythrocytes. The buffy coat, which contains the CTCs, white blood cells, and
platelets, is removed and added to the commercially available cocktail per the kit protocol.
Ficoll enrichment and separation of the CTCs will then be performed. The isolated CTCs will
then be used for further downstream characterization and experimentation which will include,
but not limited to: identification of CTC number, growth of CTCs in vitro and in vivo, and
identification/characterization of CTC adhesion molecules which allow binding to human
peritoneum. Any unused blood or component of blood not utilized in the experiment will be
assigned a unique identifier and de-identified of patient for future cross-reference and
stored at -80 degrees Fahrenheit at the University of Florida for potential future
experiments or repeat CTC isolation.
Participant Data Collection On all enrolled subjects, the following de-identified
information will be collected: participant demographic data, clinical and pathologic data,
and data on cancer recurrence and overall survival.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03500068 -
Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study.
|
N/A | |
Not yet recruiting |
NCT05489458 -
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
|
||
Recruiting |
NCT02310230 -
An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy
|
N/A | |
Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT03513705 -
Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)
|
N/A | |
Completed |
NCT01808638 -
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00226746 -
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT03432624 -
Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer
|
N/A | |
Recruiting |
NCT02451384 -
According CTC to Compare the Influences of Different Methods to Remove the PDAC
|
N/A | |
Recruiting |
NCT02529579 -
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06447662 -
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
|
Phase 1 | |
Recruiting |
NCT02817308 -
Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas
|
N/A | |
Completed |
NCT00471146 -
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
|
Phase 3 | |
Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
Terminated |
NCT01413451 -
Amatuximab for High Mesothelin Cancers
|
Early Phase 1 | |
Recruiting |
NCT03403101 -
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT02928081 -
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
|
N/A | |
Completed |
NCT05723978 -
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
|
||
Completed |
NCT04146441 -
Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05621824 -
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
|